TORONTO, Nov. 19, 2013 /PRNewswire/ - Covalon Technologies Ltd. (the "Company"
or "Covalon") (TSXV: COV), an advanced medical technologies company,
will showcase new products at MEDICA the world's largest medical
technology trade fair, November 20 to 23in Düsseldorf, Germany.
Brian Pedlar, Covalon's Chief Executive Officer said, "Since we
announced the transformative license agreement with Molnlycke earlier
this month, the amount of interest in our new product pipeline has
spiked significantly. As a result, we have accelerated the unveiling
of our FDA-cleared ColActive® Transfer wound dressing and our CovaCoat A.I. Anti Infective
coatings. Along with our proven ColActive® Plus wound dressings and SilverCoat Antimicrobial Foley Catheters, our
strong pipeline of new products and technologies, which includes
ColActive® Transfer and CovaCoat A.I., positions Covalon well as a partner for
wound care, urological, vascular access, surgical and orthopaedic
companies and distributors."
The latest addition to the patented ColActive family of wound care
products being showcased at MEDICA is ColActive® Transfer, Covalon's bio-degradable wound dressing that stimulates wound
healing responses in difficult to heal wounds, while allowing wound
fluids to pass through the dressing. ColActive® Transfer is designed to protect new-growth tissue in wounds undergoing
treatment and is FDA approved for sale in the United States. Along
with the introduction of ColActive® Transfer, Covalon anticipates entering the nearly US$500 million
negative pressure dressing and kit market.
Covalon will also be unveiling its new patented CovaCoat A.I. Anti
Infective coating technology that provides antimicrobial and
anti-thrombogenic properties, without eluting antimicrobial agents from
the surface of medical devices. Covalon's CovaCoat A.I. Anti Infective
Foley Catheter significantly reduces biofilm formation on urinary
catheters, the formation of which is a major source of hospital
acquired infections. The use of CovaCoat A.I. on vascular access
devices provides both anti-thrombogenic and antimicrobial
characteristics without the downside of delivering potentially
cytotoxic antimicrobial agents directly into the bloodstream.
Covalon Technologies Ltd. researches, develops and commercializes new
healthcare technologies that help save lives around the world.
Covalon's patented technologies, products and services address the
advanced healthcare needs of medical device companies, healthcare
providers and individual consumers. Covalon's technologies are used to
prevent, detect and manage medical conditions in specialty areas such
as wound care, tissue repair, infection control, disease management,
medical device coatings and biocompatibility. To learn more about
Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The
forward-looking statements are often, but not always, identified by the
use of words such as "seek", "anticipate", "plan, "estimate", "expect",
"intend" and statements that an event or result "may", "will",
"should", "could" or "might" occur or be achieved and other similar
expressions. These forward-looking statements involve risk and
uncertainties, including the difficulty in predicting product
approvals, acceptance of and demands for new products, the impact of
the products and pricing strategies of competitors, delays in
developing and launching new products, the regulatory environment,
fluctuations in operating results and other risks, any of which could
cause results, performance, or achievements to differ materially from
the results discussed or implied in the forward-looking statements.
Many risks are inherent in the industry; others are more specific to
the Company. Investors should consult the Company's ongoing quarterly
filings for additional information on risks and uncertainties relating
to these forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The Company assumes no
obligation to update or alter any forward-looking statements whether as
a result of new information, further events or otherwise.
SOURCE Covalon Technologies Ltd.